Advertisement

Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse

  • Satoko OkaEmail author
  • Kazuo Ono
  • Masaharu Nohgawa
Original Article

Abstract

In the present study, we investigated the effects of immunophenotyping on prognosis of diffuse large B cell lymphoma (DLBCL) with central nervous system (CNS) relapse treated with rituximab-CHOP (R-CHOP). CNS relapse occurred in 9.5% of DLBCL patients. At the diagnosis of DLBCL, CD25 was detected in 14.3% of cases. CD25 positivity correlated with an advanced stage, higher R-IPI, higher CNS-IPI, the presence of B symptoms, the presence of extranodal involvement >1, and bone involvement. Moreover CNS relapse was more frequently observed in patients with CD25+ than in those with CD25-. The univariate analysis showed that an advanced stage, high-risk R-IPI, high-risk CNS-IPI, bone involvement, and CD25+ were associated with shorter overall survival (OS). The multivariate analysis confirmed that CD25+ and high-risk CNS-IPI were independent adverse prognostic factors for shorter OS. A Kaplan-Meier analysis revealed the potential of CD25+ as a prognostic factor in patients with CNS relapse and that it correlated with shorter survival. The present results showed that the expression of CD25 in DLBCL patients with CNS relapse was associated with the patient prognosis independent other prognostic factors. The establishment of a treatment strategy for CNS relapse patients with CD25+ DLBCL cells is needed to improve poor outcomes.

Keywords

Diffuse large B cell lymphoma Central nervous system relapse CD25 Rituximab 

Notes

Compliance with Ethical Standards

Conflict of Interest

Satoko Oka declares that she has no conflicts of interest in the present study.

Kazuo Ono declares that he has no conflicts of interest in the present study.

Masaharu Nohgawa declares that he has no conflicts of interest in the present study.

Human Studies

This article does not contain any studies with human participants performed by any of the authors.

Informed Consent

These patients provided their written informed consent to receive each regimens, and treatments were administered according to the principles of the Declaration of Helsinki and this study was approved by the institutional ethics committee.

References

  1. 1.
    Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Ann Oncol 18:149–157CrossRefGoogle Scholar
  2. 2.
    Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K (2012) Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 103:245–251CrossRefGoogle Scholar
  3. 3.
    Avilés A, Jesús Nambo M, Neri N (2013) Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center. Med Oncol 30:520CrossRefGoogle Scholar
  4. 4.
    Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima Y (2011) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma 52:2270–2275CrossRefGoogle Scholar
  5. 5.
    Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST (2011) Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 90:809–818CrossRefGoogle Scholar
  6. 6.
    Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ (2016) CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 34:3150–3156CrossRefGoogle Scholar
  7. 7.
    Chin CK, Cheah CY (2017) How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 130:867–874CrossRefGoogle Scholar
  8. 8.
    Hu W, Wang X, Yang R, Bi L, Xie Y, Zhang Z, Lu H, Wu L (2017) Expression of CD56 is a risk factor for acute lymphocytic leukemia with central nervous system involvement in adults. Hematology. 22:81–87CrossRefGoogle Scholar
  9. 9.
    Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Iris Lim H, Martin P, Cohen JB, Evens A, al-Mansour Z, Singavi A, Fenske TS, Blum KA (2016) De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol 91:395–399CrossRefGoogle Scholar
  10. 10.
    Flynn MJ, Hartley JA (2017) The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer. Br J Haematol 179:20–35CrossRefGoogle Scholar
  11. 11.
    Nakase K, Kita K, Anazawa H, Hoshino K, Shirakawa S, Tanaka I, Tsudo M (1994) Induction of interleukin-2 receptor alpha chain expression of immature acute myelocytic leukemia cells. Leuk Res 18:269–274CrossRefGoogle Scholar
  12. 12.
    Nakase K, Kita K, Nasu K, Ueda T, Tanaka I, Shirakawa S, Tsudo M (1994) Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 46:179–183CrossRefGoogle Scholar
  13. 13.
    Tesch H, Günther A, Abts H et al (1993) Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease. Am J Pathol 142:1714–1720PubMedPubMedCentralGoogle Scholar
  14. 14.
    Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27:1–18CrossRefGoogle Scholar
  15. 15.
    Hashimoto Y, Yokohama A, Saitoh A, Nakahashi H, Toyama K, Mitsui T, Koiso H, Saitoh T, Handa H, Uchiumi H, Jinbo T, Murayama K, Matsumoto M, Sawamura M, Karasawa M, Murakami H, Hirato J, Nojima Y, Kojima M, Tsukamoto N (2013) Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases. J Clin Exp Hematop 53(3):197–205CrossRefGoogle Scholar
  16. 16.
    Yoshida N, Oda M, Kuroda Y et al (2013) Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS One 8:e78730CrossRefGoogle Scholar
  17. 17.
    Geng H, Brennan S, Milne TA et al (2012) Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov 2:1004–1023CrossRefGoogle Scholar
  18. 18.
    Lee JW, Chen Z, Geng H et al (2015) CD25(IL2RA) orchestrates negative feedback control and stabilizes oncogenic signaling strength in acute lymphoblastic leukemia. Blood 126:1434CrossRefGoogle Scholar
  19. 19.
    Fujiwara S, Muroi K, Hirata Y, Sato K, Matsuyama T, Ohmine K, Suzuki T, Ozaki K, Mori M, Nagai T, Tanaka A, Ozawa K (2013) Clinical features of de novo CD25(+) diffuse large B-cell lymphoma. Hematology. 18:14–19CrossRefGoogle Scholar
  20. 20.
    Fujiwara S, Muroi K, Tatara R, Matsuyama T, Ohmine K, Suzuki T, Mori M, Nagai T, Tanaka A, Ozawa K (2014) Clinical features of de novo CD25-positive follicular lymphoma. Leuk Lymphoma 55:307–313CrossRefGoogle Scholar
  21. 21.
    Ibrahim S, Keating M, Do KA et al (2001) CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 98:181–186CrossRefGoogle Scholar
  22. 22.
    Tanimoto T, Kusumi E, Hosoda K et al (2012) CNS prophylaxis in diffuse large B-cell lymphoma. Lancet. 379:1485–1486CrossRefGoogle Scholar
  23. 23.
    Oki Y, Noorani M, Lin P et al (2014) Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166:891–901CrossRefGoogle Scholar
  24. 24.
    Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS (2014) Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 124:2354–2361CrossRefGoogle Scholar
  25. 25.
    Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 15:129–133CrossRefGoogle Scholar
  26. 26.
    Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 21:1046–1052CrossRefGoogle Scholar
  27. 27.
    Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S, Ishigatsubo Y (2010) Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 85:6–10PubMedGoogle Scholar
  28. 28.
    Shahab N, Doll DC (1999) Testicular lymphoma. Semin Oncol 26:259–269PubMedGoogle Scholar
  29. 29.
    Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thiéblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK, International Extranodal Lymphoma Study Group (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international Extranodal lymphoma study group. J Clin Oncol 21:20–27CrossRefGoogle Scholar
  30. 30.
    Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM (2002) Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 43:1783–1788CrossRefGoogle Scholar
  31. 31.
    Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA (2012) Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 118:2944–2951CrossRefGoogle Scholar
  32. 32.
    Phillips EH, Kirkwood AA, Lawrie A et al (2016) Low rates of CNS relapse in high risk DLBCL patients treated with R-CODOX-M and R-IVAC: results from a phase 2UK NCRI/Bloodwise trial. Blood 128:1855CrossRefGoogle Scholar
  33. 33.
    Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis L, Mellinghoff IK (2019) Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 133:436–445CrossRefGoogle Scholar
  34. 34.
    Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595–1607CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  1. 1.Division of Hematology, Japanese Red Cross Society Wakayama Medical CenterWakayamaJapan
  2. 2.Division of Pathology, Japanese Red Cross Society Wakayama Medical CenterWakayamaJapan

Personalised recommendations